Red Cat Holdings, Inc. (RCAT) stands out as a drone technology company specializing in robotic hardware and software solutions for military, government, and commercial operations. While it doesn't track a traditional index, its portfolio aligns closely with the high-growth theme of unmanned aerial systems (UAS) and defense robotics. The company primarily operates through subsidiaries like Teal Drones and FlightWave, offering key products such as the Black Widow and Edge 130 drones.
In my view, RCAT's exposure is heavily weighted toward the aerospace and defense sector within Industrials, with revenue stemming from U.S. military contracts, NATO allies, and international security applications. Top areas include drone manufacturing, swarm robotics through recent acquisitions like Apium Swarm Robotics, and partnerships such as Arastelle for advanced capabilities. This concentrated focus on defense drones contributes to the recent volatility, as the stock tends to react sharply to news on contracts, production scaling, and earnings amid strong sector demand.
Over the last 30 days, RCAT dropped from approximately $17.00 to $13.35, marking a -21% decline. The move was volatile and downward-trending, kicked off by an 18% single-day plunge after earnings, followed by range-bound trading around $12.50-$14.00 as profit-taking continued.
For the past quarter, the stock edged down -2% from about $13.67 to $13.35. Performance stayed relatively flat with elevated volatility—early gains came from acquisition news and contract wins, but these were offset by the late-March correction. Trading volume spiked during key events, underscoring the stock's sensitivity to company developments. I also checked this using Tickeron’s AI Screener to see how RCAT compares to peers in the sector.
The main trigger for RCAT's -21% decline was the March 18 earnings release, which showed record Q4 revenue of $26.2 million (up 1,985% YoY) but an EPS loss of -$0.17, missing estimates of -$0.14. Near-zero gross margins, no formal FY2026 guidance due to production delays, and rising costs raised concerns about profitability and execution, leading to an 18% drop the next day.
Additional pressure stemmed from profit-taking after hitting a 52-week high near $18.78, dilution overhang, and broader small-cap weakness. Even with positive developments like NATO orders for Black Widow drones and acquisitions of Apium Swarm Robotics and Quaze Technologies, sentiment turned cautious on margins and scaling. The aerospace and defense sector's strength—from global conflicts and U.S. military demand—offered some support, but company-specific issues drove the downside.
RCAT's modest -2% quarterly decline hid stronger underlying momentum earlier, driven by defense sector tailwinds and company milestones. Positives included expanded NATO and Ukraine drone roles, partnerships like Arastelle, a 520% production capacity increase, and acquisitions enhancing swarm tech.
From what I see, macro factors like record global defense spending—at post-Cold War highs—and drone market growth (projected CAGR 9-16%) bolstered the theme. Yet, the late-quarter earnings reaction, execution risks, and thin margins during rapid scaling pulled performance back. Institutional interest persists, but small-cap dynamics in this high-growth niche fuel the volatility.
In my research process, I rely on Tickeron’s AI Screener, an AI-powered tool for discovering stocks and ETFs through filters on technical patterns, fundamentals, trends, volatility, and signals. It scans thousands of assets using criteria like industry, market cap, indicators, price patterns, and metrics, helping pinpoint trade ideas, breakouts, and opportunities faster than manual methods. For dynamic sectors like aerospace and defense, it's invaluable for data-driven insights on RCAT and peers—I've used it to uncover sector trends and comparable plays efficiently.
One thing that stands out is the upcoming Q1 2026 earnings on May 7, where I'll be looking for updates on revenue growth, margin improvements, and production ramps toward 1,000 Black Widow units monthly. Sector-wise, drone demand from U.S. military and NATO should hold amid geopolitical tensions.
Keep an eye on macro elements like defense budget approvals, interest rates affecting small-cap valuations, and inflation on costs. Peers like AVAV and drone ETFs such as DRNZ or JEDI can indicate thematic strength. Risks involve execution delays, margin pressure, and dilution; potential catalysts include new contracts and acquisition integrations. This is important because it could signal whether RCAT regains momentum.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
RCAT may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In of 35 cases where RCAT's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are .
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 13 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where RCAT advanced for three days, in of 258 cases, the price rose further within the following month. The odds of a continued upward trend are .
The 10-day RSI Indicator for RCAT moved out of overbought territory on June 03, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 33 similar instances where the indicator moved out of overbought territory. In of the 33 cases, the stock moved lower in the following days. This puts the odds of a move lower at .
The Momentum Indicator moved below the 0 level on June 11, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on RCAT as a result. In of 86 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .
The Moving Average Convergence Divergence Histogram (MACD) for RCAT turned negative on June 10, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 43 similar instances when the indicator turned negative. In of the 43 cases the stock turned lower in the days that followed. This puts the odds of success at .
RCAT moved below its 50-day moving average on June 16, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for RCAT crossed bearishly below the 50-day moving average on June 18, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In of 17 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are .
The 50-day moving average for RCAT moved below the 200-day moving average on June 25, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where RCAT declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
The Aroon Indicator for RCAT entered a downward trend on May 27, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (6.775) is normal, around the industry mean (10.849). P/E Ratio (0.000) is within average values for comparable stocks, (92.779). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (4.079). Dividend Yield (0.000) settles around the average of (0.019) among similar stocks. P/S Ratio (21.008) is also within normal values, averaging (36.950).
The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 73, placing this stock slightly better than average.
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating fairly steady price growth. RCAT’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Industry AerospaceDefense